Micro-Flow Imaging: Estimation of the Contribution of Key Factors to the Variability of Subvisible Particle Count Measurement by a Nested Statistical Analysis

References

1. 1.↵
   1. Ripple D. C.,
   2. Dimitrova M. N.

   Protein Particles: What We Know and What We Do Not Know. J. Pharm. Sci. 2012, 101 (10), 3568–3579.

   OpenUrlPubMedGoogle Scholar
2. 2.↵
   1. Corvari V.,
   2. Narhi L. O.,
   3. Spitznagel T. M.,
   4. Afonina N.,
   5. Cao S.,
   6. Cash P.,
   7. Cecchini I.,
   8. DeFelippis M. R.,
   9. Garidel P.,
   10. Herre A.,
   11. Koulov A. V.,
   12. Lubiniecki T.,
   13. Mahler H.-C.,
   14. Mangiagalli P.,
   15. Nesta D.,
   16. Perez-Ramirez B.,
   17. Polozova A.,
   18. Rossi M.,
   19. Schmidt R.,
   20. Simler R.,
   21. Singh S.,
   22. Weiskopf A.,
   23. Wuchner K.

   Subvisible (2–100 μm) Particle Analysis during Biotherapeutic Drug Product Development: Part 2, Experience with the Application of Subvisible Particle Analysis. Biologicals 2015, 43 (6), 457–473.

   OpenUrlGoogle Scholar
3. 3.↵
   1. Mathonet S.,
   2. Mahler H.-C.,
   3. Esswein S. T.,
   4. Mazaheri M.,
   5. Cash P. W.,
   6. Wuchner K.,
   7. Kallmeyer G.,
   8. Das T. K.,
   9. Finkler C.,
   10. Lennard A.

   A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2016, 70 (4), 392–408.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
4. 4.↵
   1. Langille S. E.

   Particulate Matter in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
5. 5.↵
   1. Filipe V.,
   2. Hawe A.,
   3. Carpenter J. F.,
   4. Jiskoot W.

   Analytical Approaches to Assess the Degradation of Therapeutic Proteins. TrAC, Trends Anal. Chem. 2013, 49, 118–125.

   OpenUrlGoogle Scholar
6. 6.↵
   1. Zölls S.,
   2. Tantipolphan R.,
   3. Wiggenhorn M.,
   4. Winter G.,
   5. Jiskoot W.,
   6. Friess W.,
   7. Hawe A.

   Particles in Therapeutic Protein Formulations, Part 1: Overview of Analytical Methods. J. Pharm. Sci. 2012, 101 (3), 914–935.

   OpenUrlCrossRefPubMedGoogle Scholar
7. 7.↵
   1. den Engelsman J.,
   2. Garidel P.,
   3. Smulders R.,
   4. Koll H.,
   5. Smith B.,
   6. Bassarab S.,
   7. Seidl A.,
   8. Hainzl O.,
   9. Jiskoot W.

   Strategies for the Assessment of Protein Aggregates in Pharmaceutical Biotech Product Development. Pharm. Res. 2011, 28 (4), 920–933.

   OpenUrlCrossRefPubMedGoogle Scholar
8. 8.↵
   1. Ratanji K. D.,
   2. Derrick J. P.,
   3. Dearman R. J.,
   4. Kimber I.

   Immunogenicity of Therapeutic Proteins: Influence of Aggregation. J. Immunotoxicol. 2014, 11 (2), 99–109.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
9. 9.↵
   1. Frahm G. E.,
   2. Pochopsky A. W. T.,
   3. Clarke T. M.,
   4. Johnston M. J. W.

   Evaluation of Microflow Digital Imaging Particle Analysis for Sub-Visible Particles Formulated with an Opaque Vaccine Adjuvant. PLoS One 2016, 11 (2), e0150229.

   OpenUrlGoogle Scholar
10. 10.↵
    1. Zölls S.,
    2. Weinbuch D.,
    3. Wiggenhorn M.,
    4. Winter G.,
    5. Friess W.,
    6. Jiskoot W.,
    7. Hawe A.

    Flow Imaging Microscopy for Protein Particle Analysis: A Comparative Evaluation of Four Different Analytical Instruments. AAPS J. 2013, 15 (4), 1200–1211.

    OpenUrlGoogle Scholar
11. 11.↵
    1. Sharma D. K.,
    2. King D.,
    3. Oma P.,
    4. Merchant C.

    Micro-Flow Imaging: Flow Microscopy Applied to Sub-Visible Particulate Analysis in Protein Formulations. AAPS J. 2010, 12 (3), 455–464.

    OpenUrlPubMedGoogle Scholar
12. 12.↵
    1. Sharma D. K.,
    2. Oma P.,
    3. Pollo M. J.,
    4. Sukumar M.

    Quantification and Characterization of Subvisible Proteinaceous Particles in Opalescent mAb Formulations Using Micro-Flow Imaging. J. Pharm. Sci. 2010, 99 (6), 2628–2642.

    OpenUrlPubMedGoogle Scholar
13. 13.↵
    1. Sharma D. K.,
    2. King D.,
    3. Merchant C.

    Reference Material Development for Calibration and Verification of Image-Based Particle Analyzers. Int. J. Pharm. 2011, 416 (1), 293–295.

    OpenUrlPubMedGoogle Scholar
14. 14.↵
    1. Weinbuch D.,
    2. Zölls S.,
    3. Wiggenhorn M.,
    4. Friess W.,
    5. Winter G.,
    6. Jiskoot W.,
    7. Hawe A.

    Micro-Flow Imaging and Resonant Mass Measurement (Archimedes): Complementary Methods to Quantitatively Differentiate Protein Particles and Silicone Oil Droplets. J. Pharm. Sci. 2013, 102 (7), 2152–2165.

    OpenUrlGoogle Scholar
15. 15.↵
    1. Scherer T. M.,
    2. Leung S.,
    3. Owyang L.,
    4. Shire S. J.

    Issues and Challenges of Subvisible and Submicron Particulate Analysis in Protein Solutions. AAPS J. 2012, 14 (2), 236–243.

    OpenUrlPubMedGoogle Scholar
16. 16.↵
    1. Ríos Quiroz A.,
    2. Finkler C.,
    3. Huwyler J.,
    4. Mahler H.-C.,
    5. Schmidt R.,
    6. Koulov A. V.

    Factors Governing the Accuracy of Subvisible Particle Counting Methods. J. Pharm. Sci. 2016, 105 (7), 2042–2052.

    OpenUrlGoogle Scholar
17. 17.↵
    1. Rauk A. P.,
    2. Griffiths K. L.,
    3. Gossage M. D.,
    4. Weiss W. F. IV.

    . Variability in Flow-Imaging Microscopy Measurements and Considerations for Biopharmaceutical Development. J. Pharm. Sci. 2016, 105 (11), 3296–3303.

    OpenUrlGoogle Scholar
18. 18.↵
    1. Ríos Quiroz A.,
    2. Lamerz J.,
    3. Da Cunha T.,
    4. Boillon A.,
    5. Adler M.,
    6. Finkler C.,
    7. Huwyler J.,
    8. Schmidt R.,
    9. Mahler H.-C.,
    10. Koulov A. V.

    Factors Governing the Precision of Subvisible Particle Measurement Methods: A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe. Pharm. Res. 2016, 33 (2), 450–461.

    OpenUrlGoogle Scholar
19. 19.↵
    1. Werk T.,
    2. Volkin D. B.,
    3. Mahler H.-C.

    Effect of Solution Properties on the Counting and Sizing of Subvisible Particle Standards as Measured by Light Obscuration and Digital Imaging Methods. Eur. J. Pharm. Sci. 2014, 53, 95–108.

    OpenUrlGoogle Scholar
20. 20.↵
    1. Majumdar S.,
    2. Ford B. M.,
    3. Mar K. D.,
    4. Sullivan V. J.,
    5. Ulrich R. G.,
    6. D'Souza A. J. M.

    Evaluation of the Effect of Syringe Surfaces on Protein Formulations. J. Pharm. Sci. 2011, 100 (7), 2563–2573.

    OpenUrlPubMedGoogle Scholar
21. 21.↵
    1. Vlieland N. D.,
    2. Nejadnik M. R.,
    3. Gardarsdottir H.,
    4. Romeijn S.,
    5. Sediq A. S.,
    6. Bouvy M. L.,
    7. Egberts A. C. G.,
    8. van den Bemt B. J. F.,
    9. Jiskoot W.

    The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors. Pharm. Res. 2018, 35 (2), 42.

    OpenUrlGoogle Scholar
22. 22.↵
    1. Pedersen J. S.,
    2. Persson M.

    Unmasking Translucent Protein Particles by Improved Micro-Flow Imaging™ Algorithms. J. Pharm. Sci. 2014, 103 (1), 107–114.

    OpenUrlGoogle Scholar
23. 23.↵
    1. Saller V.,
    2. Hediger C.,
    3. Matilainen J.,
    4. Grauschopf U.,
    5. Bechtold-Peters K.,
    6. Mahler H.-C.,
    7. Friess W.

    Influence of Particle Shedding from Silicone Tubing on Antibody Stability. J. Pharm. Pharmacol. 2018, 70 (5), 675–685.

    OpenUrlGoogle Scholar
24. 24.↵
    1. Weiss W. F. IV.,
    2. Young T. M.,
    3. Roberts C. J.

    Principles, Approaches, and Challenges for Predicting Protein Aggregation Rates and Shelf Life. J. Pharm. Sci. 2009, 98 (4), 1246–1277.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
25. 25.↵
    1. Wuchner K.,
    2. Büchler J.,
    3. Spycher R.,
    4. Dalmonte P.,
    5. Volkin D. B.

    Development of a Microflow Digital Imaging Assay to Characterize Protein Particulates during Storage of a High Concentration IgG1 Monoclonal Antibody Formulation. J. Pharm. Sci. 2010, 99 (8), 3343–3361.

    OpenUrlPubMedGoogle Scholar